We've changed the way you complete courses

In response to user feedback we have simplified the way courses can be completed.

Until now you needed to complete the topics and modules in order, from start to finish. But from today you can complete them in any order you wish.

Just visit any topic that interests you, and when you are ready mark it as completed by clicking the green 'Mark complete' button at the bottom of the page.

Once you have completed all of the topics in a module an assessment will be provided for you.

Complete all the assessments to finish the course.

Thanks, I've got it! X

The most recent group of glucose-lowering therapies that we took from type 2 diabetes and imported as adjunct therapies in people with type 1 diabetes are the SGLT inhibitors. We now have studies with SGLT-2 inhibitors but also studies with a combined SGLT-2 and SGLT-1 inhibitor, namely sotagliflozin, as adjunct therapies in people with type 1 diabetes. And here I refer you to the module on the use of SGLT inhibitors in people with type 1 diabetes.
Play the audio to learn more about SGLT inhibitors
  • non-selective SGLTs (phlorizin)
  • selective SGLT-2 (canagliflozin, dapagliflozin, empagliflozin, ipragliflozin)
  • SGLT-1/SGLT-2 inhibitor (sotagliflozin)
Select image for larger view
Select image for larger view
Select image for larger view
Select image for larger view
Select image for larger view

Cariou B, Charbonnel B. Sotagliflozin as a potential treatment for type 2 diabetes mellitus. Expert Opin Investig Drugs. 2015;24(12):1647-56
http://www.ncbi.nlm.nih.gov/pubmed/26548423